| Members |
targetComponentId |
| Local flap of skin to head or neck NEC |
Reconstruction with local flap |
| Local flap reconstruction by V-Y advancement - action |
Local flap reconstruction by advancement - action (qualifier value) |
| Local pedicle V-Y flap reconstruction - action |
Local flap reconstruction - action |
| Local pedicle flap reconstruction - action (qualifier value) |
Local flap reconstruction - action |
| Local pedicle island flap reconstruction - action (qualifier value) |
Local flap reconstruction - action |
| Local sensory skin flap NEC |
Local sensory skin flap (procedure) |
| Local subcutaneous pedicle flap, myocutaneous NEC |
Reconstruction using local subcutaneous pedicle myocutaneous flap |
| Local subcutaneous pedicle island flap to head or neck NEC |
Reconstruction using local subcutaneous pedicle island flap |
| Local subcutaneous pedicle island flap, axial pattern NEC |
Reconstruction using local axial pattern subcutaneous pedicle island flap |
| Local subcutaneous pedicle island flap, axial pattern, to head or neck |
Reconstruction of skin using local subcutaneous pedicle island axial pattern skin flap (procedure) |
| Local subcutaneous pedicle island flap, fasciocutaneous NEC |
Reconstruction using local subcutaneous pedicle fasciocutaneous flap |
| Local subcutaneous pedicle island flap, random pattern NEC |
Reconstruction using local subcutaneous pedicle island random pattern flap (procedure) |
| Local subcutaneous pedicle island flap, random pattern, to head or neck |
Reconstruction of skin using local subcutaneous pedicle island random pattern skin flap (procedure) |
| Local subcutaneous pedicle skin flap NOS |
Reconstruction of skin using local subcutaneous pedicle skin flap (procedure) |
| Local transposition flap, axial pattern NEC |
Local transposition flap - axial pattern |
| Local transposition flap, random pattern NEC |
Local transposition flap - random pattern |
| Localization-related epilepsy (disorder) |
Partial seizure |
| Localized adult periodontitis |
Localized chronic periodontitis |
| Locked twins obstructing labor (disorder) |
Interlocked twins |
| Lomefloxacin 0.3% eye drops (product) |
Lomefloxacin 3 mg/mL eye solution |
| Long atonic seizure |
Atonic seizure |
| Long-acting thyroid stimulator (substance) |
Thyroid stimulating immunoglobulins |
| Loperamide 2mg oral lyophilisate tablet (product) |
Loperamide hydrochloride 2 mg oral tablet |
| Loperamide hydrochloride 1mg/5mL conventional release oral syrup |
Product containing precisely loperamide hydrochloride 200 microgram/1 milliliter conventional release oral solution (clinical drug) |
| Loperamide hydrochloride 1mg/5mL sugar free syrup (product) |
Product containing precisely loperamide hydrochloride 200 microgram/1 milliliter conventional release oral solution (clinical drug) |
| Loperamide hydrochloride 2mg orodispersible tablet |
Loperamide hydrochloride 2 mg oral tablet |
| Loperamide hydrochloride+simethicone (product) |
Product containing loperamide and simeticone (medicinal product) |
| Lophortyx gambelii |
Callipepla gambelii (organism) |
| Loracarbef 100mg/5mL oral suspension (product) |
Product containing precisely loracarbef 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Loracarbef 100mg/5mL suspension (product) |
Product containing precisely loracarbef 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Loracarbef 200mg/5mL oral suspension (product) |
Loracarbef 40 mg/mL oral suspension |
| Loracarbef 200mg/5mL suspension (product) |
Loracarbef 40 mg/mL oral suspension |
| Loracarbef, anhydrous 100mg/5mL powder (product) |
Product containing precisely loracarbef 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Loracarbef, anhydrous 200mg/5 mL powder (product) |
Loracarbef 40 mg/mL oral suspension |
| Loratadine 10mg/10mL syrup (product) |
Loratadine 1 mg/mL oral solution |
| Loratadine+pseudoephedrine sulfate 5mg/120mg m/r tablet (product) |
Loratadine and pseudoephedrine only product in oral dose form |
| Loratadine+pseudoephedrine sulfate 5mg/120mg prolonged-release oral tablet |
Loratadine and pseudoephedrine only product in oral dose form |
| Lordosis in hip disease |
Lordosis deformity of spine due to disorder of hip region |
| Lordosis in skeletal dysplasia |
Lordosis deformity of spine due to congenital skeletal dysplasia |
| Lovastatin 10mg m/r tablet (product) |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Lovastatin 10mg prolonged-release oral tablet (product) |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Lovastatin 20mg m/r tablet (product) |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Lovastatin 20mg prolonged-release oral tablet |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Lovastatin 40mg m/r tablet (product) |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Lovastatin 40mg prolonged-release oral tablet |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Lovastatin 60mg m/r tablet (product) |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Lovastatin 60mg prolonged-release oral tablet (product) |
Product containing only lovastatin in oral dose form (medicinal product form) |
| Low cervical cesarean section |
Lower uterine segment caesarean section |
| Low pressure hydrocephalus |
hydrocéphalie à pression normale |
| Lower leg flap |
Flap (substance) |
| Lower leg random pattern flap |
Random pattern flap |
| Lower limb flap |
Flap (substance) |
| Lower uterine segment cesarean delivery NEC |
Lower uterine segment caesarean section |
| Lucilia sericata |
Phaenicia sericata |
| Lumbar somatic dysfunction (finding) |
Somatic dysfunction of lumbar region (finding) |
| Lumbar spine DXA scan |
Dual energy X-ray absorptiometry of lumbar spine (procedure) |
| Lumbar spine DXA scan |
Dual energy X-ray absorptiometry of lumbar spine (procedure) |
| Lumbar spine DXA scan T score |
Dual energy X-ray photon absorptiometry lumbar spine scan T score (observable entity) |
| Lumbar spine DXA scan T score |
Dual energy X-ray photon absorptiometry lumbar spine scan T score (observable entity) |
| Lumbar spine DXA scan Z score |
Dual energy X-ray photon absorptiometry lumbar spine scan Z score (observable entity) |
| Lumbar spine DXA scan Z score |
Dual energy X-ray photon absorptiometry lumbar spine scan Z score (observable entity) |
| Lumbar spine DXA scan |
Dual energy X-ray absorptiometry of lumbar spine (procedure) |
| Lumbar spine DXA scan T score |
Dual energy X-ray photon absorptiometry lumbar spine scan T score (observable entity) |
| Lumbar spine DXA scan Z score |
Dual energy X-ray photon absorptiometry lumbar spine scan Z score (observable entity) |
| Lung TNM finding (finding) |
American Joint Committee on Cancer allowable value |
| Lupus erythematosus cell (cell) |
Lupus erythematosus cell |
| Luteinizing hormone releasing factor (substance) |
Gonadotropin releasing factor (substance) |
| Luteinizing hormone releasing factor preparation (product) |
LH-RH |
| Lutropin alfa 75iu injection (pdr for recon)+solvent (product) |
Product containing precisely lutropin alfa 75 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Lutropin alfa 75iu injection (pdr for recon)+solvent (product) |
Product containing precisely lutropin alfa 75 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Luys' nucleus |
Structure of subthalamic nucleus of Luy (body structure) |
| Lymphadenopathy-associated virus, type II (LAV-II) |
virus de l'immunodéficience humaine de type 2 |
| Lymphangioma |
Benign lymphangioma |
| Lymphatic incision NOS |
Incision of lymphatic system structure |
| Lymphatic incision NOS |
Incision of lymphatic system structure |
| Lymphocystis disease virus |
Genus Lymphocystivirus |
| Lymphoid leukemia (category) |
Lymphoid leukaemia |
| Lymphoma morphology |
Malignant lymphoma |
| Lymphoproliferative disease |
Lymphoproliferation of uncertain behavior (morphologic abnormality) |
| Lymphosarcoma cell leukemia |
Lymphoid leukaemia |
| Lymphosarcoma cell leukemia |
Lymphoid leukaemia |
| Lymphosarcoma of extranodal AND/OR solid organ site (disorder) |
Non-Hodgkin's lymphoma (clinical) |
| Lymphosarcoma of intra-abdominal lymph nodes |
Mixed cell type lymphosarcoma of intra-abdominal lymph nodes |
| Lymphosarcoma of intrapelvic lymph nodes |
Non-Hodgkin's lymphoma (clinical) |
| Lymphosarcoma of intrathoracic lymph nodes |
Mixed cell type lymphosarcoma of intrathoracic lymph nodes |
| Lymphosarcoma of lymph nodes of axilla AND/OR upper limb (disorder) |
Non-Hodgkin's lymphoma (clinical) |
| Lymphosarcoma of lymph nodes of head, face, and neck |
Non-Hodgkin's lymphoma (clinical) |
| Lymphosarcoma of lymph nodes of inguinal region AND/OR lower limb (disorder) |
Non-Hodgkin's lymphoma (clinical) |
| Lymphosarcoma of lymph nodes of multiple sites |
Malignant lymphoma of lymph nodes |
| Lymphosarcoma of spleen |
Non-Hodgkin's lymphoma (clinical) |
| Lyophilized powder for conventional release liposomal suspension for injection (dose form) |
Lyophilized powder for conventional release suspension for injection (dose form) |
| Lysis of adhesions of abdomen (procedure) |
Lysis of adhesions of peritoneum |
| Lückenschadel (disorder) |
Craniolacunia |
| M+nage E trois (social status) (finding) |
Ménage à trois |
| M0 category (finding) |
American Joint Committee on Cancer cM0 (qualifier value) |
| M1 (IV): Distant metastasis (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1 (IVB): Distant metastasis (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1 category (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1: Distant metastasis [includes metastasis to ipsilateral supraclavicular lymph nodes] (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1: Distant metastasis, includes separate tumor nodule(s) in a different lobe (ipsilateral or contralateral) (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1a (III): gestational trophoblastic tumor extends to the lungs with or without genital tract involvement (finding) |
American Joint Committee on Cancer cM1a (qualifier value) |
FHIR